HERZLIYA, Israel, Dec. 30, 2014 /PRNewswire/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the
"Company"), a clinical-stage biopharmaceutical company focused on
the acquisition, development and commercialization of
pharmaceutical products for the treatment of unmet clinical needs,
today announced that the Company's shareholders approved the
appointment of two new members to the Board of Directors,
Doron Turgeman and Shlomo Shalev.
Doron Turgeman, 46, has
significant public company experience with both NASDAQ and TASE
listed companies. Mr. Turgeman is currently the Chief
Executive Officer of B Communications (BCOM) and Internet Gold
(IGLD), both of which are listed on the NASDAQ. He has gained
considerable experience in mergers and acquisitions involving both
debt and equity, with, among others, the purchase of the
controlling interest of Bezeq by B Communications. He is
knowledgeable in capital markets in Israel, the US and Europe as well as SEC and TASE reporting
standards. Throughout his career, he has proved to be a
strong manager and has developed close relationships with key
constituents throughout the industry.
Mr. Turgeman holds a B.A. degree in Economics and Accounting
from the Hebrew University of Jerusalem
and is a certified public accountant in Israel.
Shlomo Shalev, 52, most recently
served as Chairman of the Board of Micronet, a TASE listed
company. In addition to serving as a board member on a number
of NASDAQ and TASE listed companies, such as OphirOptronics, Arel
Communications and PowerDsine, Mr. Shalev was the Senior Vice
President of Investments for Ampal. He has also worked on a
number of transactions in mergers and acquisitions and initial
public offerings. With an educational background in
economics, Mr. Shalev was Israel's
Consul for Economic Affairs and the Economic Advisor to the
Director General, Ministry of Industry and Trade.
Mr. Shalev holds an MBA from the University
of San Francisco and a B.A. degree in Economics from the
University of Ben Gurion,
Beer Sheva, Israel.
Josh Levine, Chief Executive
Officer of XTL, commented, "We look forward to drawing from the
considerable experience that Doron and Shlomo have gained
throughout their distinguished careers. As a dually listed
company, their public company background will be a great resource
to the company as we remain focused on developing our core assets,
hCDR1 for Lupus and rHuEPO for Multiple Myeloma. With these two new
members joining our Board of Directors and the recent appointments
of Dr. Jonathan Schapiro and Dr.
Dobroslav Melamed, we believe that
we have constructed a strong board that will help guide us as we
continue on the path of development."
About XTL Biopharmaceuticals Ltd. ("XTL")
XTL Biopharmaceuticals Ltd., a biopharmaceutical company,
focuses on the acquisition, development, and commercialization of
pharmaceutical products for the treatment of unmet clinical needs.
XTL is focused on late stage clinical development of drugs for the
treatment of lupus, multiple myeloma and schizophrenia.
XTL is a public company traded on the Nasdaq Capital Market
(NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTL). XTL
shares are included in the following indices: Tel-Aviv Biomed,
Tel-Aviv MidCap, and Tel-Aviv Tech Index.
Cautionary Statement
Some of the statements included in this press release may be
forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. Please see the risk
factors associated with an investment in our ADSs or ordinary
shares which are included in our Annual Report on Form 20-F as
filed with the U.S. Securities and Exchange Commission on
April 2, 2014.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/xtl-biopharmaceuticals-annual-general-meeting-of-shareholders-appoints-two-new-members-to-the-board-of-directors-300014532.html
SOURCE XTL Biopharmaceuticals Ltd.